Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CLSA Drops BEONE MEDICINES (06160.HK) TP to $286.2 as 4Q25 NP Misses
Recommend 3 Positive 4 Negative 2 |
||||
|
||||
|
BEONE MEDICINES (06160.HK)'s 4Q25 results were mixed, with sales increasing by 32.8% YoY, beating market consensus, according to CLSA's research report. However, net profit missed expectation due to an one-off impairment. Management guided for sales of US$6.2 billion to US$6.4 billion in 2026, representing a YoY growth of approx. 20%. CLSA believed that the Company has multiple late-stage pipeline catalysts in the future, including BCL-2, BTK CDAC and CDK4. After factoring in the results, the broker chopped its target prices for BEONE MEDICINES' H-shares/ US stock/ A-shares from $288/ US$491.2/ RMB423.4 to $286.2/ US$485.1/ RMB384.5, with ratings kept at Outperform. AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
